325.1 ð é«åžçç
325.1.1 Stage I (T1-T2a, N0)
- Surgical resection (lobectomy preferred over wedge or sublobar)
- VATS / robotic approach
- Adjuvant chemotherapy NOT routine for stage IA (debated for IB > 4 cm)
- Adjuvant osimertinib (ADAURA) for EGFR+ stage IB-IIIA (resected)
325.1.2 Stage II (T2b-T3, N0; T1-T2, N1)
- Surgical resection
- Adjuvant chemotherapy (cisplatin-based) â survival
- Adjuvant atezolizumab if PD-L1 ⥠1% (IMpower010)
- Adjuvant osimertinib if EGFR+ (ADAURA)
325.1.3 Stage IIIA (T3-T4, N1; T1-T2, N2)
- Multimodality treatment:
- Surgery + adjuvant
- Neoadjuvant therapy
- Concurrent chemoradiation + durvalumab (PACIFIC) for unresectable
- Highly individualized
325.1.4 Stage IIIB-IIIC (unresectable locally advanced)
- Concurrent chemoradiation (cisplatin + etoposide or carboplatin + paclitaxel)
- Durvalumab consolidation à 12 months (PACIFIC 2018)
- Osimertinib consolidation for EGFR+ (LAURA 2024)
325.1.5 Stage IV (Metastatic)
- Molecular profiling-driven first
- Targeted therapy if actionable mutation
- Immunotherapy + chemotherapy otherwise
325.1.6 Approach
- Lobectomy = standard (versus wedge or segmentectomy)
- JCOG0802 (2022): segmentectomy non-inferior for stage IA †2 cm â practice-changing for small peripheral
- Sublobar resection: limited lung function or small tumor
- Pneumonectomy: only when necessary; higher morbidity
- VATS or robotic (less invasive)
- Open for complex
325.1.7 Lymph Node Dissection
- Systematic lymph node sampling or dissection
- Mediastinal staging
- Predicts prognosis
325.1.8 Adjuvant Therapy
Chemotherapy: - Cisplatin-based (cisplatin + vinorelbine, gemcitabine, docetaxel, or pemetrexed for non-squamous) - For Stage IB ⥠4 cm, II, IIIA - 4 cycles - â Survival 4-5% absolute
Atezolizumab (IMpower010, 2021): - Stage II-IIIA + PD-L1 ⥠1% - 16 cycles q3 weeks - â DFS
Osimertinib (ADAURA, 2020): - EGFR+ (exon 19 del or L858R) - Stage IB-IIIA - Adjuvant 3 years - Significantly improves DFS (⥠80%)
325.1.10 Neoadjuvant Immunotherapy (NEW 2022-2024)
CheckMate 816 (2022): - Resectable NSCLC stage IB-IIIA - Neoadjuvant nivolumab + chemo à 3 cycles vs chemo - â Pathologic complete response (pCR) 24% vs 2.2% - â EFS
AEGEAN (2023): - Neoadjuvant + adjuvant durvalumab + chemo - â pCR, EFS
KEYNOTE-671 (2023): - Pembrolizumab perioperative (neoadjuvant + adjuvant) - â OS (first to show)
Practice-Changing: - Resectable NSCLC stage IB-IIIA â neoadjuvant chemo + IO + surgery + adjuvant IO
325.1.11 EGFR Mutation
First-Line: - Osimertinib (Tagrisso) 80 mg daily â preferred (FLAURA 2018) - â Median OS to 38.6 months (vs 31.8 with gefitinib) - CNS penetration excellent - Side effects: rash, diarrhea, ILD (uncommon, watch), QTc
Resistance Mechanisms: - C797S mutation (acquired) - MET amplification (~ 20%) - Histologic transformation (SCLC, squamous) - Bypass pathways
Post-Osimertinib: - Amivantamab (MET + EGFR bispecific) + chemo (MARIPOSA-2) - Re-biopsy critical
Other EGFR Mutations: - Exon 20 insertion: less responsive to osimertinib; amivantamab, mobocertinib - T790M acquired: osimertinib responsive
325.1.12 ALK Rearrangement
First-Line: - Alectinib (Alecensa) (ALEX 2017) â median PFS 34.8 months - Brigatinib (ALTA-1L) - Lorlatinib (CROWN â most potent, longest PFS but more CNS side effects) - All have CNS penetration
Resistance: - Next-gen ALK TKI (lorlatinib for many) - Combination strategies emerging
325.1.13 ROS1 Rearrangement
- Crizotinib (older)
- Entrectinib (CNS penetration)
- Repotrectinib (2023) â addresses resistance, broader
325.1.14 KRAS G12C
- Sotorasib (Lumakras) â CodeBreaK 100 (2020)
- Adagrasib (Krazati) â KRYSTAL-1 (2022)
- ~ 35% response rate; ~ 30% median survival
- Better than chemo but lower than EGFR/ALK targets
- Resistance mechanisms studied
325.1.15 MET Exon 14 Skipping
- Capmatinib (Tabrecta)
- Tepotinib (Tepmetko)
- GEOMETRY-mono, VISION trials
325.1.16 HER2 Mutation
- Trastuzumab deruxtecan (Enhertu) â DESTINY-Lung01/02
- ADC (antibody-drug conjugate)
- Response 50% in HER2-mutant NSCLC
325.1.19 RET Fusion (Rare; 1-2%)
- Selpercatinib (Retsevmo) â LIBRETTO
- Pralsetinib (Gavreto) â ARROW
325.1.20 PD-L1 ⥠50% (TPS Score)
- Pembrolizumab monotherapy (KEYNOTE-024)
- 1st-line
- Median OS 30 months
- 6% complete response
325.1.21 PD-L1 1-49% or < 1%
- Combination: pembrolizumab + chemo (KEYNOTE-189 non-squamous; KEYNOTE-407 squamous)
- Standard of care 1st-line
325.1.22 Nivolumab + Ipilimumab + Limited Chemo
- CheckMate 9LA, CheckMate 227
- Alternative regimens
- Some patients
325.1.27 Concurrent Chemoradiation
- Cisplatin + etoposide + radiation (60-70 Gy)
- OR carboplatin + paclitaxel + radiation
- For unresectable
325.1.28 Durvalumab Consolidation (PACIFIC 2018)
- 1 year à 12 months
- â Median OS 47.5 vs 29.1 months
- Class I
325.1.29 Osimertinib Consolidation (LAURA 2024)
- For EGFR+ stage III unresectable
- Median PFS 39.1 months
- Practice-changing
325.1.32 Treatment
- CNS-penetrant TKIs: osimertinib, alectinib, brigatinib, lorlatinib, entrectinib
- Stereotactic radiosurgery (SRS): for limited brain mets
- Whole-brain radiotherapy (WBRT): for multiple or symptomatic
- Surgery: for single large symptomatic
- Pembrolizumab: CNS-penetrating to extent
325.1.33 Leptomeningeal Disease
- More refractory
- Intrathecal chemotherapy
- Osimertinib for EGFR+
- Poor prognosis
325.1.34 Older Adults
- Performance status + frailty important
- Single-agent therapy often
- TKIs well-tolerated
- IO tolerable in many
325.1.36 Pregnancy
- Rare consideration
- Many drugs teratogenic
- Multidisciplinary
325.1.36.1 𩺠åºé鿥
- Stage I-II: lobectomy + adjuvant chemo (II+); adjuvant osimertinib for EGFR+ (ADAURA)
- Stage III unresectable: chemoradiation + durvalumab (PACIFIC) or osimertinib (LAURA EGFR+)
- Stage IV with driver: targeted therapy first (EGFR, ALK, ROS1, KRAS G12C, MET, HER2, BRAF, NTRK, RET)
- Stage IV PD-L1 ⥠50%: pembrolizumab monotherapy
- Stage IV PD-L1 < 50% or driver-negative: pembrolizumab + chemo
- Neoadjuvant IO: CheckMate 816, KEYNOTE-671 for resectable stage IB-IIIA
- Brain mets: CNS-penetrant TKIs (osimertinib, alectinib, lorlatinib) + SRS